Search

Your search keyword '"Claggett, B"' showing total 421 results
Start Over Author "Claggett, B" Search Limiters Peer Reviewed
421 results on '"Claggett, B"'

2. Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial

Author

Peikert, A, primary, Bart, B A, additional, Vardeny, O, additional, Vaduganathan, M, additional, Claggett, B L, additional, Desai, A S, additional, Jhund, P S, additional, Kosiborod, M N, additional, Lam, C S P, additional, Martinez, F A, additional, De Boer, R A, additional, Hernandez, A F, additional, Shah, S J, additional, Mc Murray, J J V, additional, and Solomon, S D, additional

Published
2023
Full Text
View/download PDF

3. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Author

Chatur, S, primary, Vaduganathan, M, additional, Claggett, B L, additional, Desai, A S, additional, Docherty, K F, additional, Jhund, P S, additional, De Boer, R A, additional, Hernandez, A F, additional, Inzucchi, S E, additional, Kosiborod, M N, additional, Lam, C S P, additional, Martinez, F A, additional, Shah, S J, additional, Mcmurray, J V, additional, and Solomon, S D, additional

Published
2023
Full Text
View/download PDF

5. Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

Author

Wang, X, primary, Lam, C S P, additional, Claggett, B, additional, Miao, M, additional, Shah, S J, additional, Jhund, P S, additional, Desai, A S, additional, Chiang, C, additional, Pham, V N, additional, Han, Y, additional, Kitakaze, M, additional, Langkilde, A M, additional, Mcmurray, J J V, additional, Solomon, S D, additional, and Vaduganathan, M, additional

Published
2023
Full Text
View/download PDF

6. Standardized longitudinal strain curves stratified by age and sex in healthy individuals: The Copenhagen City Heart Study

Author

Christensen, J, primary, Simonsen, J O, additional, Modin, D, additional, Skaarup, K, additional, Lassen, M C H, additional, Johansen, N D, additional, Sanchez-Martinez, S, additional, Claggett, B L, additional, Marott, J L, additional, Jensen, G B, additional, Schnohr, P, additional, Moegelvang, R, additional, and Biering-Soerensen, T, additional

Published
2023
Full Text
View/download PDF

7. Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Author

Wang, X, primary, Chatur, S, additional, Lu, H, additional, Claggett, B, additional, Skali, H, additional, Vaduganathan, M, additional, Minamisawa, M, additional, Inciardi, R M, additional, Shah, A M, additional, Packer, M, additional, Pitt, B, additional, Rouleau, J, additional, Pfeffer, M A, additional, Mcmurray, J J V, additional, and Solomon, S D, additional

Published
2023
Full Text
View/download PDF

8. Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial

Author

Weinrauch LA, Claggett B, Liu J, Finn PV, Weir MR, Weiner DE, and D'Elia JA

Subjects
Renal transplant non-cardiovascular death allograft failure smoking outcomes infectious death, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Larry A Weinrauch,1–4 Brian Claggett,1,4 Jiankang Liu,1 Peter V Finn,1 Matthew R Weir,5 Daniel E Weiner,6 John A D’Elia2–4 1Cardiovascular Division, Brigham and Women’s Hospital, 2Kidney and Hypertension Section, Joslin Diabetes Center, 3Department of Medicine, Beth Israel Deaconess Hospital, 4Harvard Medical School, Boston, MA, 5Division of Nephrology, Department of Medicine, University of Maryland, College Park, MD, 6Division of Nephrology, Tufts University School of Medicine, Boston, MA, USA Background: Tobacco use remains an international health problem with between 10% and 40% of adults currently using tobacco. Given the rising number of patients either awaiting or having received a kidney transplant and the absence of smoking cessation as the criterion for transplantation in guidelines, we explored the association between smoking status and clinical outcomes in kidney transplant recipients. Patients and methods: In this post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplant trial, the associations between smoking status, defined as never having smoked, formerly or currently smoking, and both all-cause mortality and graft survival were assessed using Cox proportional hazards models. Fatal events were centrally adjudicated into prespecified categories: all-cause, cardiovascular and non-cardiovascular causes. Graft loss was defined as return to dialysis or retransplantation. Clinical Trials URL: http://www.clinicaltrials.gov/show/NCT00064753. Results: Among 4110 transplant recipients, there were 451 current smokers and 1611 former smokers. The mortality rate per 100 patient-years was 4.0 (71 deaths) for smokers, 3.5 (226 deaths) for former smokers and 2.4 (116 deaths) for never smokers. Hazard ratio for mortality for current smokers was 1.70 (CI=1.26–2.29, p=0.001) and for former smokers was 1.21 (0.98–1.50, p=0.08) with 1.0 representing never smokers. As the number of cardiovascular deaths was similar in each group (all p>0.3), the differences between groups was driven by non-cardiovascular death rates. Current smokers (2.39; 1.62–3.61, p100% increased risk of non-cardiovascular death, 70% greater risk of all-cause mortality and a 50% greater risk of graft loss, a risk not seen in former smokers. These findings confirm previous non-adjudicated observations that smoking is associated with adverse clinical outcomes and suggest that more emphasis should be placed on smoking cessation prior to kidney transplantation. Keywords: tobacco, infection, infectious death, transplant loss, graft loss, non-cardiovascular mortality, diabetes

Published
2018

9. Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results

Author

Weinrauch LA, Liu J, Claggett B, Finn PV, Weir MR, and D'Elia JA

Subjects
Calcium Channel Blockers Renal Transplant Infection Death Non-cardiovascular, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Larry A Weinrauch,1–4 Jiankang Liu,1 Brian Claggett,1 Peter V Finn,1 Matthew R Weir,5 John A D’Elia2–4 1Cardiovascular Division, Brigham and Women’s Hospital, 2Kidney and Hypertension Section, Joslin Diabetes Center, 3Department of Medicine, Beth Israel Deaconess Hospital, 4Harvard Medical School, Boston, MA, 5Division of Nephrology, Department of Medicine, University of Maryland, Baltimore, MD, USA Introduction: Single-center and observational studies have suggested that calcium channel blocking agents may decrease the expression of sepsis in individual populations. In the renal transplant population, a role for calcium channel blockers in allograft protection and in prevention of sepsis has been postulated. We hypothesized that any important survival benefit or risk related to chronic use of calcium channel blocking agents should be discernable through an analysis of a large database of stable recipients of renal allografts who had enrolled in a large international trial.Methods: A retrospective analysis of 4,110 renal transplant recipients who enrolled in the international Folic Acid for Vascular Outcome Reduction in Transplantation trial between 2002 and 2007 and were followed until 2010 was undertaken comparing cohorts (FAVORIT) of patients either taking (n=1,436) or not taking (n=2,674) calcium channel blocking medications. The endpoint was all-cause mortality (cardiovascular, noncardiovascular mortality, or unknown). Results were adjusted for country, age, race, sex, smoker, systolic blood pressure, diabetes mellitus, low-density lipoprotein, and chronic kidney disease status.Results: There were no statistically significant differences in incidence rates of cardiovascular, noncardiovascular, and all-cause mortality between patients taking or not taking calcium channel blocking medications.Conclusion: Although physiologic reasoning and small series results suggest a benefit for calcium channel blocking agents for allograft protection and sepsis prevention in immunosuppressed patients, we find no clear survival benefit in a large international renal transplant trial. Keywords: sepsis, immunosuppression, allograft survival, kidney transplant, calcium channel blockade, mortality

Published
2017

10. Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial

Author

Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn P, Liu J, Claggett B, and Monaco AP

Subjects
Diabetes Renal Transplant Immunosuppression Medical Therapy Cardiovascular Events, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Larry A Weinrauch,1–4 John A D’Elia,2–4 Matthew R Weir,5 Suphamai Bunnapradist,6 Peter Finn,1 Jiankang Liu,1 Brian Claggett,1 Anthony P Monaco3,4 1Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, 2Kidney and Hypertension Section,Joslin Diabetes Center, Boston, MA, 3Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA, 4Harvard Medical School, Boston MA, 5University of Maryland School of Medicine, Baltimore, MD, 6Division of Nephrology, Department of Medicine University of California at Los Angeles, Los Angeles, CA, USA Abstract: Although survival has improved for kidney transplant recipients over the past ­several decades, long-term survival in diabetic cohorts still is significantly less than that of non-diabetic cohorts. We hypothesized that among stable kidney transplant recipients, there might be differences between subgroups with and without diabetes with respect to prevalence of prior cardiovascular events and post-transplant antihypertensive and immunosuppressive therapy. We performed a post hoc analysis of participants in the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial, a multicenter international trial of 4110 prevalent kidney transplant recipients enrolled from 2002 to 2007 evaluating the effect of homocysteine-lowering vitamin therapy on cardiovascular outcomes. There were 2447 participants without diabetes, 166 with type 1 diabetes, and 1447 with type 2 diabetes at study entry, which occurred on average 4 years post-transplant. Recipients with diabetes had a greater prevalence of prior cardiovascular events, were more likely to have required multiple medications to control hypertension, and were more likely to have received tacrolimus as opposed to cyclosporine than the non-diabetic transplant recipients (all p

Published
2017

12. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

Author

Jering, K, primary, Claggett, B, additional, Pfeffer, M A, additional, Granger, C, additional, Kober, L, additional, Lewis, E F, additional, Maggioni, A P, additional, Mann, D L, additional, McMurray, J J V, additional, Prescott, M F, additional, Rouleau, J L, additional, Solomon, S D, additional, Steg, P G, additional, Von Lewinski, D, additional, and Braunwald, E, additional

Published
2022
Full Text
View/download PDF

13. Atrial fibrillation in patients with high-risk acute myocardial infarction – the PARADISE-MI trial

Author

Cikes, M, primary, Jering, K, additional, Claggett, B, additional, Amir, O, additional, Cadena Bonfanti, A J, additional, Cho, M C, additional, Granger, C, additional, Gullestad, L M, additional, Kao, H L, additional, Morais, J, additional, Tanguay, J F, additional, Tokmakova, M, additional, Widimsky, P, additional, and Solomon, S D, additional

Published
2022
Full Text
View/download PDF

14. Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: insight from PARADISE MI trial

Author

Schou, M, primary, Claggett, B, additional, Fernandez, A, additional, Filippatos, G, additional, Granger, C, additional, Jering, K, additional, Maggioni, A, additional, McCausland, F, additional, Nunez Villota, J, additional, Rouleau, J L, additional, Mody, F G, additional, Van Der Meer, P, additional, Vinereanu, D, additional, Zhou, Y, additional, and Kober, L, additional

Published
2022
Full Text
View/download PDF

15. PARADISE-MI – event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40

Author

Petrie, M, primary, Solomon, S, additional, Claggett, B L, additional, Jering, K, additional, Steg, G, additional, Granger, C, additional, Lewis, E, additional, Kober, L, additional, Mann, D, additional, Rouleau, J L, additional, McMurray, J J, additional, Maggioni, A, additional, Braunwald, E, additional, and Pfeffer, M A, additional

Published
2022
Full Text
View/download PDF

16. Risk of acute myocardial infarction, stroke and thromboembolism following COVID-19 vaccination compared to testing positive for COVID-19 infection: a nationwide cohort study of 4.6 mio individuals

Author

Lassen, M H, primary, Modin, D, additional, Skaarup, K G, additional, Claggett, B, additional, Solomon, S D, additional, Fralick, M, additional, Staehr-Jensen, J U, additional, Sivapalan, P, additional, Schou, M, additional, Krause, T G, additional, Hviid, A, additional, Koeber, L, additional, Torp-Pedersen, C, additional, Gislason, G, additional, and Biering-Soerensen, T, additional

Published
2022
Full Text
View/download PDF

17. Proteomic biomarkers associated with incident heart failure and frailty in late life

Author

Ramonfaur, D R, primary, Buckley, L B, additional, Arthur, V A, additional, Claggett, B C, additional, Ndumele, C N, additional, Walker, K A W, additional, Kitzman, D K, additional, Konety, S K, additional, Schrack, J S, additional, Liu, F L, additional, Windham, B G W, additional, Palta, P P, additional, Coresh, J C, additional, Yu, B Y, additional, and Shah, A M S, additional

Published
2022
Full Text
View/download PDF

18. A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)

Author

McDowell, K, primary, Simpson, J, additional, Jhund, P S, additional, Abraham, W T, additional, Claggett, B, additional, Cunningham, J, additional, Desai, A S, additional, Kober, L, additional, Prescott, M, additional, Rouleau, J L, additional, Swedberg, K, additional, Zile, M R, additional, Solomon, S D, additional, Packer, M, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

19. Trajectory of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction and association with cardiac structure and function

Author

Platz, E, primary, Claggett, B, additional, Jering, K S, additional, Kovacs, A, additional, Cikes, M, additional, Winzer, E B, additional, Rad, A, additional, Lefkowitz, M, additional, Gong, J, additional, Kober, L, additional, McMurray, J J V, additional, Solomon, S D, additional, and Shah, A, additional

Published
2022
Full Text
View/download PDF

23. Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction

Author

Cunningham, J, primary, Zhang, L, additional, Claggett, B, additional, Abraham, W, additional, Jhund, P, additional, Kober, L, additional, Packer, M, additional, Rouleau, J, additional, Zile, M, additional, Prescott, M, additional, Mendelson, M, additional, Lefkowitz, M, additional, McMurray, J, additional, Solomon, S, additional, and Chutkow, W, additional

Published
2022
Full Text
View/download PDF

25. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Author

Cikes M., Planinc I., Claggett B., Cunningham J., Milicic D., Sweitzer N., Senni M., Gori M., Linssen G., Shah S. J., Packer M., Pfeffer M., Zile M. R., Anand I., Chiang L. -M., Lam C. S. P., Redfield M., Desai A. S., McMurray J. J. V., Solomon S. D., Cikes, M, Planinc, I, Claggett, B, Cunningham, J, Milicic, D, Sweitzer, N, Senni, M, Gori, M, Linssen, G, Shah, S, Packer, M, Pfeffer, M, Zile, M, Anand, I, Chiang, L, Lam, C, Redfield, M, Desai, A, Mcmurray, J, and Solomon, S

Subjects
heart failure with preserved ejection fraction, heart failure outcome, sacubitril/valsartan, echocardiography, atrial fibrillation
Abstract

Objectives: In this study, the authors sought to assess the relationship between AFF and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with HFpEF enrolled in the PARAGON-HF trial. Background: Atrial fibrillation and flutter (AFF) are common in heart failure with preserved ejection fraction (HFpEF) and increase the risk of adverse outcomes. Methods: A total of 4,776 patients formed 3 groups: those with AFF according to electrocardiography (ECG) at enrollment (n = 1,552; 33%), those with history of AFF but without AFF on ECG at enrollment (n = 1,005; 21%), and those without history of AFF or AFF on ECG at enrollment (n = 2,219, 46%). We assessed outcomes, treatment response to sacubitril/valsartan in each group, and the risk associated with first-detected AFF in patients without any known AFF. The primary outcome was a composite of total heart failure hospitalizations and cardiovascular death. Results: History of AFF and AFF at enrollment were associated with higher risk of the primary outcome (risk ratio [RR]: 1.36 [95% CI: 1.12-1.65] and RR: 1.31 [1.11-1.54], respectively), than no AFF. Neither history of AFF nor AFF at enrollment modified the treatment effect of sacubitril/valsartan. Post randomization AFF occurred in 12% of patients without previous AFF and was associated with 2.8-fold higher risk of the primary outcome, but it was not influenced by sacubitril/valsartan. Conclusions: History of AFF and AFF on ECG at enrollment were associated with a higher risk of the primary outcome. First-detected AFF was not influenced by sacubitril/valsartan, yet it was associated with increased risk of all subsequent outcomes and may represent a potential target for future HFpEF trials. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)

Published
2022

32. Sex Disaggregated Analysis of Risk Factors for Adverse Outcomes in Hypertrophic Cardiomyopathy

Author

Butters, A., primary, Arnott, C., additional, Sweeting, J., additional, Claggett, B., additional, Ashley, E., additional, Parikh, V., additional, Colan, S., additional, Day, S., additional, Owens, A., additional, Helms, A., additional, Saberi, S., additional, Jacoby, D., additional, Michels, M., additional, Olivotto, I., additional, Pereira, A., additional, Rossano, J., additional, Wittekind, S., additional, Ware, J., additional, Atherton, J., additional, Semsarian, C., additional, Lakdawala, N., additional, Ho, C., additional, and Ingles, J., additional

Published
2022
Full Text
View/download PDF

33. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial

Author

Gori M, Senni M, Claggett B, Liu J, Maggioni AP, Zile M, Prescott MF, Van Veldhuisen DJ, Zannad F, Pieske B, Lam CSP, Rouleau J, Jhund P, Packer M, Pfeffer MA, Lefkowitz M, Shi V, McMurray JJV, Solomon SD, Gori, M, Senni, M, Claggett, B, Liu, J, Maggioni, A, Zile, M, Prescott, M, Van Veldhuisen, D, Zannad, F, Pieske, B, Lam, C, Rouleau, J, Jhund, P, Packer, M, Pfeffer, M, Lefkowitz, M, Shi, V, Mcmurray, J, and Solomon, S

Subjects
sacubitril/valsartan, high-sensitivity troponin, HFpEF
Abstract

Objectives: This study examined the relationship among high-sensitivity troponin-T (hs-TnT), outcomes, and treatment with sacubitril/valsartan in patients with heart failure (HF) and preserved ejection fraction (HFpEF). Background: hs-TnT is a marker of myocardial injury in HF. Methods: The PARAGON-HF trial randomized 4,796 patients with HFpEF to sacubitril/valsartan or valsartan. We compared the risk of the composite outcome of cardiovascular death (CVD) and total HF hospitalization (HHF) according to hs-TnT. We also assessed the effect of allocated treatment on hs-TnT. Results: hs-TnT was available in 1,141 patients (24%) at run-in (median value: 17 ng/L) and 1,260 (26%) at randomization, with 58.3% having hs-TnT >14 ng/L (upper limit of normal). During a median follow-up of 34 months, there were 393 outcome events (82 CVD, 311 HHF). Adjusting for demographics, comorbidities, left ventricular ejection fraction (LVEF), and N-terminal pro B-type natriuretic peptide (NT-proBNP), log-hs-TnT at randomization was an independent predictor of the composite outcome (HR: 1.38; 95% CI: 1.19-1.59; P < 0.001). Compared with valsartan, sacubitril/valsartan significantly reduced hs-TnT by 9% at week 16 (P < 0.001). Patients whose hs-TnT decreased from randomization to 16 weeks to at or below the median value of 17 ng/L subsequently had a lower risk of CVD/HHF compared with those with persistently elevated hs-TnT (P = 0.046). Patients with higher baseline hs-TnT (>17 ng/L) appeared to have a greater benefit from sacubitril/valsartan treatment when accounting for other potential effect modifiers (P interaction = 0.07). Conclusions: Higher baseline hs-TnT was associated with increased risk of CVD/HHF, whereas hs-TnT decrease at 16 weeks led to lower subsequent risk of CVD/HHF compared with those who had persistently elevated values. Sacubitril/valsartan significantly reduced hs-TnT compared with valsartan. hs-TnT may be helpful in identifying patients with HFpEF who are more likely to benefit from sacubitril/valsartan.

Published
2021

35. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction

Author

Pfeffer, MA, Claggett, B, Lewis, EF, Granger, CB, Kober, L, Maggioni, AP, Mann, DL, McMurray, JJV, Rouleau, JL, Solomon, SD, Steg, PG, Berwanger, O, Cikes, M, De Pasquale, CG, East, C, Fernandez, A, Jering, K, Landmesser, U, Mehran, R, Merkely, B, Mody, FV, Petrie, MC, Petrov, I, Schou, M, Senni, M, Sim, D, van der Meer, P, Lefkowitz, M, Zhou, Y, Gong, J, Braunwald, E, Sionis A., and PARADISE-MI Invest & Comm

Abstract

Sacubitril-Valsartan in Acute Myocardial Infarction In a randomized trial, 5661 patients with acute myocardial infarction and a reduced left ventricular ejection fraction, pulmonary congestion, or both were assigned to receive either sacubitril-valsartan or ramipril. At a median of 22 months, there was no significant difference between the two groups in the incidence of death from cardiovascular causes or incident heart failure. Background In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. Methods We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. Results A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group. Conclusions Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, .)

Published
2021

39. P6350Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the spironolactone for heart failure with preserved ejection fraction (TOPCAT) trial

Author

De Marco, C, primary, Claggett, B, additional, De Denus, S, additional, Huynh, T, additional, Desai, A S, additional, Sirois, M G, additional, Jarolim, P, additional, Solomon, S D, additional, Pitt, B, additional, Rouleau, J L, additional, Pfeffer, M A, additional, and O'meara, E, additional

Published
2019
Full Text
View/download PDF

44. 1347The flu vaccine and mortality in hypertension. A Danish nationwide cohort study

Author

Modin, D, primary, Claggett, B, additional, Joergensen, M E, additional, Koeber, L, additional, Benfield, T, additional, Schou, M, additional, Jensen, J U, additional, Solomon, S, additional, Trebbien, R, additional, Fralick, M, additional, Vardeny, O, additional, Pfeffer, M A, additional, Torp-Pedersen, C, additional, Gislason, G, additional, and Biering-Soerensen, T, additional

Published
2019
Full Text
View/download PDF

45. Machine-learning analysis of myocardial deformation patterns to predict incident heart failure or death in the general population

Author

Sanchez, S, Cikes, M, Claggett, B, Duchateau, Nicolas, Piella, G, Cheng, S, Shah, A, Bijnens, B, Solomon, S, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Imagerie et modélisation Vasculaires, Thoraciques et Cérébrales (MOTIVATE), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL)

Subjects
[INFO.INFO-IM]Computer Science [cs]/Medical Imaging, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; no abstract

Published
2018

48. P6508Balance of risk and benefit of spironolactone according to renal function in heart failure patients with preserved ejection fraction

Author

Beldhuis, I E, primary, Myhre, P L, additional, Claggett, B, additional, Damman, K, additional, Fang, J C, additional, Lewis, E F, additional, O'Meara, E, additional, Pitt, B, additional, Shah, S J, additional, Voors, A A, additional, Pfeffer, M A, additional, Solomon, S D, additional, and Desai, A S, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results